Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/26/2012 | 05:50pm CET

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/15 JOHNSON & JOHNSON : ordered to pay $15M in vaginal mesh case
12/15 CONSUMERS ENERGY : Newsweek Ranks Consumers Energy as #1 Company in Michigan in ..
12/15 JOHNSON & JOHNSON : Jury awards $15 million in j&j trial
12/15 JOHNSON & JOHNSON : Janssen and Leading Advocacy Organizations Introduce Cancer...
12/14 JOHNSON & JOHNSON : Los Alamos research fundamental to first efficacy study for ..
12/14 JOHNSON & JOHNSON : Innovation Announces Launch of JLABS @ Shanghai in Collabora..
12/14 JOHNSON & JOHNSON : Bergen jury gets pelvic mesh case
12/14 JOHNSON & JOHNSON : and 4mm Navigational Bi-Directional Ablation catheters
12/14 JOHNSON & JOHNSON : J&Js Darzalex shows promise in newly-diagnosed multiple myel..
12/14 JOHNSON & JOHNSON : J&J`s Darzalex cuts risk of disease progression and death by..
More news
News from SeekingAlpha
12/16 AUTOMATIC DATA PROCESSING : Great Total Return And Recent Dividend Hike For Inco..
12/15 Just Turned 40? How To Reach A Goal Of $1.5 Million.
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Let Hitters Swing For The Fence
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,35%
P/E ratio 2017 23,89
P/E ratio 2018 19,64
EV / Sales 2017 5,24x
EV / Sales 2018 4,83x
Capitalization 383 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386
AMGEN21.32%128 515